Based on synergy observed in preclinical models [28], another strategy is combination of venetoclax with BTK inhibitors, which are administered as monotherapy for the first 2–3 cycles to allow mobilisation of CLL cells from the lymph nodes and reduction in tumour burden with a view to mitigating TLS risk. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.